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Sugar alcohol provides imaging 
contrast in cancer detection
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Hari Hariharan  1, Mohammad Haris1,2,3 & Ravinder Reddy1
clinical imaging is widely used to detect, characterize and stage cancers in addition to monitoring 
the therapeutic progress. Magnetic resonance imaging (MRi) aided by contrast agents utilizes the 
differential relaxivity property of water to distinguish between tumorous and normal tissue. Here, we 
describe an MRI contrast method for the detection of cancer using a sugar alcohol, maltitol, a common 
low caloric sugar substitute that exploits the chemical exchange saturation transfer (CEST) property of 
the labile hydroxyl group protons on maltitol (malCEST). In vitro studies pointed toward concentration 
and pH-dependent CEST effect peaking at 1 ppm downfield to the water resonance. Studies with control 
rats showed that intravenously injected maltitol does not cross the intact blood-brain barrier (BBB). in 
glioma carrying rats, administration of maltitol resulted in the elevation of CEST contrast in the tumor 
region only owing to permeable BBB. these preliminary results show that this method may lead to 
the development of maltitol and other sugar alcohol derivatives as MRI contrast agents for a variety of 
preclinical imaging applications.
Medical imaging is widely used to monitor structural, functional, and molecular changes in cancer and the use 
of contrast agents has significantly improved the detection by providing enhanced contrast between normal and 
pathological tissues1–4. Positron Emission Tomography using 18Fluoro-2-deoxy-glucose (18FDG-PET) combined 
with either computed tomography (CT) or magnetic resonance imaging (MRI) has gained widespread applica-
tion as a molecular and metabolic imaging modality of cancers based on the high glycolytic activity of tumors5,6. 
However, owing to the high metabolic activity of surrounding neurons, 18F-FDG uptake in the normal brain 
tissue limits its use for the imaging of cerebral gliomas7. In addition to conventional MRI, dynamic contrast 
enhanced (DCE) MRI utilizes the relaxivity perturbation potential of gadolinium-based contrast agents (GBCAs) 
to detect and characterize cancer8. Although, recent studies have reported the deposition of GBCAs in the brain 
and bone matrix3,9,10, further studies are required to evaluate the long-term effects of gadolinium (Gd) accumu-
lation on normal tissue function.
The Chemical Exchange Saturation Transfer (CEST) MRI technique probes the exchange of labile protons of 
the solute with bulk water protons11–15. By applying low-power frequency-selective radio-frequency (RF) pulses 
for a long time, magnetization of exchangeable protons on a metabolite can be saturated. The chemical exchange 
mediated accumulation of these saturated protons with water decreases the bulk water signal in a concentration 
and pH dependent manner14,16,17. The difference in the water signal obtained with and without RF saturation 
can be measured as the CEST contrast14,15. CEST MRI has been used to image different metabolites and macro-
molecules in vivo, with applications in several human disorders18–23. Since the CEST method provides orders of 
magnitude higher sensitivity than traditional proton MR spectroscopy (1H MRS), it enables detection of subtle 
changes in the level of metabolite of interest14,17. Various groups have reported the use of glucose and its analogues 
as CEST contrast agent to study cancer and neurodegeneration18,20,24–34.
In this study, we introduce a new contrast agent, maltitol, a sugar alcohol commonly used as a sweetener due 
to its less caloric value. We exploited the CEST behavior of labile hydroxyl (-OH) protons on maltitol with those of 
the bulk water and termed this new method as malCEST. The concentration and pH dependence of malCEST con-
trast was measured in vitro in solution phantoms. The potential of malCEST as an MR imaging method to image 
cancer was assessed in a rat glioma model and compared with gadolinium-diethylenetriamine-pentaacetic-acid 
(Gd-DTPA) contrast enhanced MRI.
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Results
Chemical evaluation of exchangeable protons of maltitol. Maltitol is a disaccharide of glucose and 
sorbitol, having 9 water exchangeable -OH groups (Fig. 1a). Chemical shift of the labile -OH protons of malti-
tol was determined using high-resolution nuclear magnetic resonance (NMR) spectroscopy. The spectra from 
200 mM maltitol (pH 7) were acquired at different temperatures (5, 15, 25, & 37 °C) on a 400 MHz NMR spec-
trometer (Bruker, Germany). Two peaks at ~0.8 and ~1.3 ppm down field of water were detected due to slower 
exchange between maltitol -OH protons and bulk water at low temperatures (Fig. 1b). The -OH peaks were found 
to broaden at higher temperatures due to faster chemical exchange and completely disappear at 37 °C. The obser-
vation of -OH peaks at ~1 ppm downfield to water signal suggests the feasibility of CEST based experiments using 
maltitol.
Evaluation of CEST effect from maltitol. The characterization of CEST effect from maltitol was per-
formed by applying a continuous low power saturating RF pulses at frequencies gradually moving away from 
the reference water peak are visualized by plotting the water saturation as a function of saturation frequency. 
The z-spectra and z-spectral asymmetry (MTRasym) curves obtained from maltitol solution showed maximal 
malCEST effect at 1 ppm (Fig. 1c). The malCEST contrast from 10 mM maltitol solution in vitro was found to be 
maximum at ~6 µT saturation power (B1) for all saturation durations (Fig. 1d). For a given B1, higher malCEST 
contrast was observed with the increase in saturation duration (Fig. 1d).
Concentration and pH dependence of malCEST contrast. The concentration dependence of 
malCEST contrast was evaluated in vitro on solution phantoms prepared at physiological pH and temperature 
(37 °C). The MTRasym@1ppm map from 10 mM phantom showed ~13% of malCEST contrast (Fig. 2a) and was lin-
early proportional to the maltitol concentration with a slope of 1.3% per mM of maltitol (Fig. 2b). The malCEST 
effect was found to be inversely proportional to pH (Fig. 2c,d). The data acquired from maltitol solution at varying 
pH depicted 14.8% increase in malCEST per unit decrease in pH. The malCEST map from 10 mM maltitol solu-
tion acquired on 7 T human MRI scanner is shown in the Supplementary Fig. 1.
CEST MRI experiments in control rats. To assess whether maltitol crosses the intact BBB, an in vivo 
study was performed on control rats (n = 3). At the given saturation parameters (2.35 µT, 2 sec), a baseline 2–3% 
MTRasym@1ppm was observed. This may be due to the endogenous metabolites with -OH groups present in the 
brain predominantly myo-inositol and glucose. The malCEST contrast maps from a normal rat brain were 
acquired at different time intervals over a period of 70 minutes during and following the intravenous injection of 
maltitol (Fig. 3a). No appreciable change in the malCEST contrast was observed in the normal rat brain over the 
period of 70 minutes (Fig. 3b) most likely due to the intact blood-brain barrier (BBB).
Figure 1. CEST effect from maltitol sweetener. (a) Chemical structure of maltitol. (b) High resolution NMR 
spectrum of 200 mM maltitol solution in PBS shows two peaks from exchangeable hydroxyl protons (-OH) 
respectively at 0.8 and 1.3 ppm at 5 °C. These peaks exchange broaden with increase in temperature and 
completely broadened at 37 °C. (c) Z-spectra (black) and asymmetry curves (blue) from 10 mM of maltitol show 
broad resonance (0–3 ppm) from exchangeable hydroxyl protons, which peaks at 1 ppm. (d) Saturation power 
and saturation dependence malCEST contrast. Higher B1 and saturation duration increase the malCEST effect.
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To evaluate the effect of intravenously injected maltitol on the blood glucose level, 50 µl of blood was collected 
every 20-minute time interval for up to period of 60 minutes. The blood glucose level during period of 60 minutes 
following the beginning of maltitol infusion was found to remain the same (Fig. 3c), indicating that there was 
no hydrolysis of maltitol into glucose and sorbitol. Further, the blood pH following maltitol administration was 
found to be unaltered until 60 minutes in three control rats.
Figure 2. MalCEST map of maltitol. (a) malCEST map obtained from 10 mM maltitol solution phantom 
at 37 °C shows homogenous contrast. (b) Plot depicts the concentration dependent malCEST contrast. (c) 
Z-spectra asymmetry curves at different pH show higher malCEST contrast with decrease in pH. (d) inverse 
linear correlation between malCEST and pH was observed.
Figure 3. MalCEST imaging in a normal rat brain. (a) CEST MRI from a normal rat brain depicts no 
appreciable change in the malCEST contrast following injection of maltitol over 70 min. (b) Data from 
the normal rats (n = 3) shows no change in malCEST contrast in the brain during and following maltitol 
administration. (c) There was no observable change in the blood glucose levels post maltitol administration.
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CEST experiments on glioma rats. To assess the potential of maltitol for providing CEST contrast to 
image cancer in vivo, we performed MR imaging experiments on rats carrying 9 L glioma. As the maltitol solu-
tion for MRI experiments was prepared in normal saline (NS), it is necessary to determine the effect of NS on 
the CEST contrast post intravenous administration. The MTRasym maps at 1 ppm shown in Fig. 4 demonstrate 
no change in the CEST contrast pre and post-NS administration indicating NS does not contribute to the CEST 
changes in further experiments. Following this, we performed MR studies including T1/T2-weighted and CEST 
MRI in glioma carrying rats (n = 5) by administrating maltitol. The T2 weighted image showed hyperinten-
sity in the tumor (Fig. 5a), correspondingly, Gd-DTPA enhanced T1-weighted image clearly highlighted the 
tumor region (Fig. 5b). The malCEST contrast measured post administration of maltitol highlighted only the 
tumor region (Fig. 5c–g) presumably due to the accumulation of maltitol in the extracellular and extravascu-
lar space (EES) because of the enhanced BBB permeability and retention effect. The MTRasym curves obtained 
pre- and post-maltitol administration clearly showed increase in the CEST contrast at 1 ppm demonstrating that 
the change is due to EES accumulation of maltitol in the tumor (Pre: 2.33 ± 0.24%, Post 40 min: 3.95 ± 0.44%; 
p < 0.001) (Fig. 6a,b). There was no appreciable change in the malCEST contrast in the normal appearing brain 
regions (Pre: 1.62 ± 0.10%, Post 40 min: 1.69 ± 0.15%; p = 0.84) (Fig. 6c), which further confirms that maltitol 
does not cross the intact BBB. In the tumor, malCEST contrast peaked at ~40 minutes during the intravenous 
administration (Fig. 6d). The change in the malCEST contrast between tumor and contralateral normal appearing 
brain (NAB) ROIs post 40 minutes from the beginning of maltitol infusion was found to be statistically significant 
(Tumor: 1.62 ± 0.10%, NAB: 0.07 ± 0.02%; p < 0.001).
Discussion
In this study, we showed the potential of a commonly used low calorific sweetener, maltitol, as an MRI con-
trast agent in imaging cancer by exploiting the exchange-based property of maltitol hydroxyl protons with those 
of bulk water. The chemical shift of the exchangeable hydroxyl protons of maltitol was found to be between 
0.7–1.4 ppm downfield of water allowing its application as a possible CEST contrast agent. Being a small molecule, 
maltitol can easily accumulate in the cancerous tissues. Moreover, maltitol does not have a metabolic fate in the 
tumor due to the absence maltase enzyme responsible for the breakdown of maltitol into glucose and sorbitol.
D‐glucose and its analogues have shown potential as CEST contrast agents for the non-invasive detection of 
various cancers in preclinical and clinical studies18,28–31,33,35–40. Dynamic glucose-enhanced (glucoCEST) MRI 
has been used to study perfusion in cancer which corroborated with DCE MRI utilizing GBCAs. Recently, glu-
coCEST has been used to evaluate the efficacy of rapamycin, a glucose transporter blocker, in preclinical model 
of glioblastoma20. This study reported a higher glucoCEST contrast from tumor post-treatment with rapamycin. 
In addition, non-metabolized glucose analogues such as 3-O-methylglucose (3-OMG), have been exploited as 
CEST contrast agents for studies in cancer and stroke24–26,28–30,32. Further, another study has shown the use of a 
non-caloric sweetener, sucralose, as a CEST contrast agent to detect glioma in a preclinical model41. There are sev-
eral other studies involving another glucose analogue, 2-deoxy-D-glucose (2DG) as CEST agent to image cerebral 
glucose uptake27 in cancer35 and Alzheimer’s Disease42.
In the normal brain, the malCEST contrast was unaltered following intravenous injection of maltitol sug-
gesting that maltitol is unable to cross the BBB. However, in the brain tumor model with compromised BBB, 
Figure 4. Normal saline perfused malCEST imaging in glioma. (a) Anatomical proton weighted image shows 
tumor as a hyperintense region. (b–e) MTRasym@1ppm maps at different time points show no appreciable change 
in the CEST contrast at 1 ppm from tumor (red outline) and normal appearing brain (black outline) regions 
following administration of normal saline (b Pre-injection; c, 10 min; d, 40 min and e, 70 min post the beginning 
of normal saline administration). (f) MTR asymmetry curves from ROIs placed in the tumor region generated 
at baseline and 40 minutes post infusion of normal saline showing unaltered MTRasym. (g) Asymmetry curves 
from ROIs placed in the NAB region generated Pre- and Post 40 minutes showing no change in MTRasym from 
normal saline. (h) ΔMTRasym@1ppm (MTRasym@1ppmPost − MTRasym@1ppmPre) contrast was unaltered during and 
following normal saline administration in both tumor and NAB ROIs.
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the injected maltitol diffuses in the tumor EES and highlights the tumor areas. Significantly higher contrast was 
observed in the tumorous region at 40 minutes during maltitol infusion, while no change in the normal appearing 
brain region was observed. The spatial extent of malCEST enhancement appeared to broadly agree with that of 
the Gd-DTPA enhancement. The current study demonstrates the potential of an alternative high-resolution MR 
method to image cancers in preclinical models. The kinetics of malCEST contrast may be further evaluated in 
different cancer types and could potentially be used as a biomarker to differentiate cancer phenotypes.
Maltitol is FDA approved to be consumed orally at very high daily dose up to several grams. The toxicity pro-
file of maltitol has been evaluated in human volunteers following varying oral dose administration, observed no 
maltitol related adverse effects except at higher doses (70 g/day) where 15–30% volunteers reported diarrhea43. 
Previous studies have shown no toxic effect of intravenously injected maltitol at a dose of ~1.25 g/kg in rats44. In 
the current study, we have used maltitol at a dose of 2.5 g/kg without any observable toxic effects. Since maltitol 
is not approved by the FDA for intravenous injection in humans, it may be a limiting factor for the clinical trans-
lation of this technique. We observed no noticeable side-effects in the rats at the dosage level used in this study. 
Further, consistent with a previous study, we observed no change in the blood glucose level post maltitol admin-
istration44. Oral vs intravenous administration has different fates of maltitol inside the body. Oral administration 
of maltitol has been shown to not increase the blood maltitol level due to its conversion into glucose and sorbitol 
by the action of maltase present in the gut45. Absence of maltase in the rest of the body may be the reason for the 
observed unaltered blood glucose levels after intravenous injection of maltitol.
Maltitol is reported to have very high clearance rate from the body as reported previously44. By 60 minutes 
following intravenous administration, maltitol is nearly cleared from the blood stream. This may be a reason for 
the lower retention of the maltitol in the EES resulting in lower observed changes in the MTRassym@1ppm. Also, it 
has been shown that intravenous injected maltitol is virtually cleared from the blood within an hour44. Further 
studies at different doses are needed to validate that the observed CEST contrast arises from maltitol accumula-
tion in the tumor.
Figure 5. The malCEST map of a rat brain tumor. (a) Anatomical T2-weighted image from axial slice showing 
the location of tumor as hyper intense region in the rat brain. (b) The T1-weighted image post Gd-DTPA 
administration highlights the tumor areas in the brain. (c–g) malCEST map from rat brain tumor shows 
increased contrast in tumor region following intravenous injection of maltitol peaking at 40 minutes following 
the start of injection (c, Pre-injection; d, 10 min; e, 40 min; f, 70 min; and g, 100 minutes post the beginning of 
maltitol administration).
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Though we have evaluated the concentration and pH dependence of the CEST effect from maltitol in vitro, this 
study lacks data on the differential dosing of malitol on the malCEST contrast in vivo. Further studies are required 
in tumor-bearing animals to optimize the dose for contrast enhancement from the EES accumulation of maltitol. 
Moreover, though the malCEST enhancement in glioma corroborated with the Gd-DTPA enhanced map, a direct 
comparison between the two techniques is beyond the scope of this study. It is noteworthy that CEST acquisition 
times are longer compared to GBCA based DCE MRI studies. Also, CEST MRI in the current study is limited 
to 2D acquisition of a thick slice to obtain sufficient signal-to-noise ratio, while the GBCA based studies can be 
performed at significantly higher in-plane resolution and 3D. Finally, the B1 power and duration optimization 
performed in vitro yielded higher optimal B1 (~6 μT) for observing malCEST, while a lower B1 (2.35 μT) was used 
for in vivo experiments. This was due to the reason that high saturation powers cause off-resonance saturation of 
water leading to the reduction in CEST amplitude, especially when the exchanging protons have a small chemical 
shift and slow chemical exchange rate46–49. Although, maltitol hydroxyl group exchange rate in vitro appears to be 
high, as the extracellular pH (pHe) in tumor tissue is lower than the normal tissue50, this would lead to a reduc-
tion in the exchange rate of the accumulated maltitol hydroxyl groups in vivo. Moreover, higher B1 power results 
lower SNR in vivo than in vitro as the water concentration is higher in vitro than in vivo (~70%)51.
In conclusion, this preliminary study paves the way for the development of maltitol and other maltitol deriva-
tives as MRI contrast agents to detect cancer and monitor therapeutic response in preclinical studies.
Materials and Methods
phantom preparation. All the solution phantoms were prepared in phosphate buffered saline (PBS) and 
the experiments were performed at 37 °C. For high-resolution 1H NMR spectroscopy, 200 mM of maltitol (Sigma 
Aldrich, USA) solution was prepared in PBS at pH 7. To measure the pH dependence of malCEST, phantoms with 
10 mM maltitol concentration in PBS were prepared at a varying pH from 6.6 to 7.4 in step of 0.2 pH unit. The pH 
was adjusted using 1N NaOH/HCl. For measuring concentration dependence of malCEST contrast, phantoms 
with 2, 4, 6, 8, and 10 mM concentrations of maltitol were prepared in PBS at pH 7.
phantom imaging. High-resolution 1H NMR phantom experiments from 200 mM maltitol solution were 
performed on a vertical bore Bruker Avance DMX 400 MHz spectrometer (Bruker Corporation, Germany), 
equipped with a 5 mm PABBI proton probe using a single pulse experiment with parameters: TR = 4 s, number of 
averages = 128. 1H MR spectra were gathered at different temperatures (5, 15, 25, 37 °C). A narrow coaxial capil-
lary containing D2O and TSP was used for locking and chemical shift reference, respectively.
Figure 6. Z-spectra and MTRasym analysis of tumor and normal appearing brain following maltitol 
administration. (a,b) Z-spectra and MTR asymmetry curves from ROIs placed in the tumor region generated 
at baseline and 40 minutes post infusion of maltitol show increased MTRasym at 1 ppm (MTRasym@1ppm). (c) 
MTRasym curves from ROIs placed in the normal appearing brain (NAB) region generated at baseline and 
post 40 minutes showing no change in MTRasym due to intact BBB. (d) ΔMTRasym@1ppm (MTRasym@1ppmPost 
− MTRasym@1ppmPre) contrast at different time points peaks at 40 minutes in the tumor ROI while NAB was 
unaltered during and following maltitol administration.
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Imaging was performed on a 9.4 T, 30 cm horizontal bore animal MRI scanner (Agilent, USA) interfaced to a 
Varian console, with a 20 mm volume coil (M2M Imaging, USA). A custom-written segmented spoiled GRE pulse 
sequence with a frequency selective continuous wave saturation preparation pulse was used to perform CEST 
experiments. The sequence parameters were: field of view (FOV) = 20×20 mm2, slice thickness = 10 mm, flip 
angle = 15°, TR = 6.2 ms, TE = 2.9 ms, matrix size = 128×128. For every 15 s, one saturation pulse was applied. 
CEST images were collected using variable saturation lengths (1 through 3 seconds) and saturation pulse ampli-
tudes (B1rms: 2 to 12 µT). For concentration and pH dependent studies, CEST images were collected using 1 second 
saturation pulse at B1rms of 7 µT for multiple frequencies (−3.4 to +3.4 ppm in 0.2 ppm steps) from bulk water. B1 
and B0 field maps were also gathered and used to correct the CEST contrast maps. Briefly, CEST data, acquired 
in the neighborhood of ±1 ppm and WASSR maps were used to generate corrected malCEST images (±1 ppm) 
using a procedure similar to that described previously41,52.
Relative B1 maps were obtained using a magnetization prepared spoiled GRE method. For B1 correction, two 
images were obtained using preparation square pulses with duration (τ) and flip angles of 30° and 60°. The RF 













where S(ø) and S(2ø) denote pixel signals in an image with preparation flip angle ø and 2ø respectively. From the 
flip angle map, a B1 field map can be obtained using the relation, B1 = ø*(360τ)−1. The coefficient B1/B1ref was used 
for B1 correction of the malCEST contrast at 1 ppm.
Rat tumor model preparation. The Institutional Animal Care and Use Committees (IACUC) of the 
University of Pennsylvania approved experimental protocols, and all experiments were carried out in accordance 
with approved IACUC guidelines.
To validate the malCEST in vivo, a rat brain tumor model was used. To develop intracranial tumors, 9 L gliosar-
coma cells were used. Syngeneic female Fisher rats (F344/NCR, four-six weeks old) weighing 130–150 grams were 
used to generate tumor-bearing rats as described previously41,53. General anesthesia was induced using 2% isoflurane 
mixed with 1 liter/min oxygen. A 10 µl suspension of 50‚000 9L cells in phosphate buffered saline was injected into 
the cortex at a depth of 3 mm with a Hamilton syringe and a 30-gauge needle using stereotactic apparatus (3 mm 
lateral and 3 mm posterior to the bregma). Five weeks after implantation of tumor cells rats were subjected to MRI.
Rat MR imaging. A total of 11 rats were used for imaging. Eight rats were administered with 9 L glioma cells 
for CEST studies following normal saline (NS, n = 3) and maltitol administration (n = 5). While the remaining 3 
rats were used as healthy controls for CEST studies following maltitol administration.
Rats were anesthetized with isoflurane (3% for induction, 1.5% maintenance) and a polyethylene catheter 
(PE50) was inserted into the tail vein for maltitol or NS injection. MRI imaging was performed on tumor bearing 
rats five weeks after 9 L cell implantation. Rats were transferred to a 9.4 T horizontal bore small animal MR scan-
ner (Varian, Palo Alto, CA) and placed in a 35 mm diameter commercial quadrature proton coil (m2m Imaging 
Corp., Cleveland, OH). Animals were kept under anesthesia (1.5% isoflurane in 1 liter/min oxygen) and their 
body temperature maintained with the air generated and blowing through a heater (SA Instruments, Inc., Stony 
Brook, NY). Respiration and body temperature were continuously monitored using an MRI compatible small 
animal monitoring system (SA Instruments, Inc., Stony Brook, NY).
CEST imaging of normal rat brain and rat brain tumors was performed using a similar pulse sequence and 
parameters as described in the case of phantom imaging except a FOV = 35 × 35 mm2, slice thickness = 3 mm, 
matrix size = 128×128, B1 = 2.35 µT, saturation length = 2 s and TR = 8 s. CEST images were collected at multiple 
frequencies (−3.4 to + 3.4 ppm in 0.2 ppm steps) from bulk water. After baseline imaging the rats were injected 
maltitol solution at bolus variable rate54 through the catheter inserted in a tail vein for a period of 60 minutes. 
Animals received a 300 µl bolus of 1 M maltitol (per 200 gm body weight) intravenously. The rate of the infusion 
was decreased manually every 1 min followed a decreasing exponential function during the first 8 min and was 
constant for the remainder of the experiment. The total volume infused was ~1.5 ml. CEST acquisitions were 
started immediately with the beginning of infusion and acquired at 30-min time interval for a total period of 
120 minutes. After CEST imaging, gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) (0.3 mmol/kg) 
was injected through tail vein and T1-weighted imaging was performed on the same anatomical slice used for 
CEST with GRE (gradient echo) sequence using following parameters: FOV = 35×35 mm2, Flip Angle = 8°, Slice 
thickness = 3 mm, matrix size = 128×128, TR = 6.2 ms, TE = 2.8 ms, and averages = 12.
Similar CEST imaging protocol was used following infusion of NS in glioma bearing rats. Blood glucose and 
pH measurement at 20, 40 and 60 minutes was also performed using a blood gas analyzer following the adminis-
tration of maltitol in normal rats.
image processing. For each pixel in the CEST-weighted images, the z-spectrum was fit to a quadratic polyno-
mial and shifted by the corresponding B0 offset. B0 corrected CEST-weighted images are obtained by evaluating the fit 
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where S0 is image with 20 ppm offset saturation. B1 inhomogeneity was then corrected linearly by pixel-wise 
dividing by the relative B1 map. ROIs were manually drawn on tumor and normal appearing brain regions. All 
image processing and data analysis were performed using software routines written in MATLAB (R2015b) as 
described in detail elsewhere14,55.
Statistics. Statistical analyses were performed using SPSS. A student’s t-test was performed to compare the 
changes in the CEST contrast in the normal appearing brain and tumor ROIs following the administration of 
maltitol intravenously. The data is presented as mean ± standard error.
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